Intelligent Bio Solutions Inc. has entered into a strategic manufacturing partnership with Syrma Johari MedTech Ltd. to scale production of its Intelligent Fingerprinting Drug Screening Reader, strengthen supply-chain resilience, and support long-term margin expansion ahead of its planned US market entry in 2026.
Under the agreement, Syrma Johari will support and expand manufacturing of the device, delivering expected annual production cost savings of more than 40%. This is projected to translate into an improvement of approximately 20 percentage points in INBS’ gross margin compared with its previous manufacturing arrangement. Syrma Johari’s manufacturing capacity is around four times INBS’ current capacity, positioning the company to meet anticipated growth in demand as commercial operations scale across multiple regions.
The partnership reduces reliance on a single supplier and enhances INBS’ global manufacturing strategy by adding capacity, flexibility, and continuity. This is expected to be particularly critical as the company prepares for broader international expansion and entry into the US market.
Syrma Johari MedTech brings more than 45 years of experience in the design, engineering, and manufacture of regulated medical devices. The company operates 14 manufacturing facilities and four design and innovation centres across India, Europe, and the United States, with a combined plant area exceeding 1.1 million square feet. Its facilities are certified to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards.
The company’s vertically integrated and export-oriented operating model supports efficiencies across sourcing, tooling, testing, and logistics. Its capabilities span electronics manufacturing, mechanical assembly, PCB fabrication, functional testing, and clean-room processes, enabling consistent, high-quality production of INBS’ fingerprint-based drug-screening reader.
Syrma Johari is also set to commission a new medical-grade plastics manufacturing facility in India in January 2026, further expanding capacity to support global demand.
Syrma Johari’s regulatory and quality-assurance infrastructure is aligned with INBS’ international growth plans, providing end-to-end quality systems, regulatory documentation, and compliance support across key jurisdictions including the US, Europe, the UK, Canada, and Asia-Pacific markets.
This is expected to support INBS as it advances regulatory pathways and increases commercial activity worldwide.
Also Read